Serum Levels of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand as Markers of Periprosthetic Osteolysis

2006 ◽  
Vol 88 (7) ◽  
pp. 1501-1509 ◽  
Author(s):  
Donatella Granchi ◽  
Andrea Pellacani ◽  
Mauro Spina ◽  
Elisabetta Cenni ◽  
Lucia Maria Savarino ◽  
...  
Keyword(s):  
Serum Levels ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Periprosthetic Osteolysis ◽  
Receptor Activator

SERUM LEVELS OF OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-κB LIGAND AS MARKERS OF PERIPROSTHETIC OSTEOLYSIS

2006 ◽  
Vol 88 (7) ◽  
pp. 1501-1509
Author(s):  
DONATELLA GRANCHI ◽  
ANDREA PELLACANI ◽  
MAURO SPINA ◽  
ELISABETTA CENNI ◽  
LUCIA MARIA SAVARINO ◽  
...  
Keyword(s):  
Serum Levels ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Periprosthetic Osteolysis ◽  
Receptor Activator

Serum Levels of Receptor Activator of Nuclear Factor κB Ligand (RANKL) in Healthy Women and Men

2007 ◽  
Vol 116 (08) ◽  
pp. 491-495 ◽  
Author(s):  
K. Kerschan-Schindl ◽  
J. Wendlova ◽  
S. Kudlacek ◽  
A. Gleiss ◽  
W. Woloszczuk ◽  
...  
Keyword(s):  
Serum Levels ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Healthy Women ◽  
Receptor Activator

Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor κB in women with postmenopausal osteoporosis

2010 ◽  
Vol 17 (1) ◽  
pp. 140-144 ◽  
Author(s):  
Rebeca Reyes-García ◽  
Manuel Muñoz-Torres ◽  
D. Fernández García ◽  
Pedro Mezquita-Raya ◽  
Jose Antonio García Salcedo ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Serum Levels ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator ◽  
Alendronate Treatment

Alterations in Serum Levels of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in Patients with Head Injury and Fracture

2008 ◽  
Vol 21 (2) ◽  
pp. 145 ◽  
Author(s):  
Shin Young Park ◽  
Kuen Tak Suh ◽  
Chang Hoon Ryu ◽  
Seung Hun Woo ◽  
Jung Sub Lee ◽  
...  
Keyword(s):  
Head Injury ◽  
Serum Levels ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator

scholarly journals Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide

2008 ◽  
Vol 158 (3) ◽  
pp. 411-415 ◽  
Author(s):  
Athanasios D Anastasilakis ◽  
Dimirtios G Goulis ◽  
Stergios A Polyzos ◽  
Spiridon Gerou ◽  
Vasiliki Pavlidou ◽  
...  
Keyword(s):  
Type I Collagen ◽  
Serum Levels ◽  
Nuclear Factor Κb ◽  
Acute Effect ◽  
Type I ◽  
Nuclear Factor ◽  
Mineral Density ◽  
Serum Samples ◽  
Established Osteoporosis ◽  
Receptor Activator

ObjectiveThe mechanisms regulating the anabolic response of the skeleton to intermittent exogenous parathyroid hormone (PTH) administration are not fully elucidated. The aim of this prospective study was to evaluate the acute effect (up to 1 month) of teriparatide (TPTD; human recombinant PTH 1–34) on serum levels of osteoprotegerin (OPG) and receptor activator for nuclear factor-κB ligand (RANKL) in women with established osteoporosis.DesignTwenty-three postmenopausal Caucasian women with established osteoporosis (mean age 66.7±1.6 years) received daily injections of 20 μg TPTD for 12 months.MethodsSerum samples for total calcium (Ca), phosphate, alkaline phosphatase, N-terminal propeptide of type I collagen, intact PTH (iPTH), OPG, and RANKL were obtained at baseline, 1 h, 1 day, and 1 month after initiation of therapy. Lumbar spine bone mineral density (BMD) was measured before and 12 months after TPTD treatment.ResultsSerum total Ca increased and iPTH gradually decreased with TPTD treatment. Serum OPG levels remained unchanged, while RANKL increased gradually during the study (P<0.001). There was no correlation between OPG or RANKL and BMD changes or iPTH levels.ConclusionsTPTD therapy in women with postmenopausal osteoporosis results in acute increase in serum RANKL levels but does not affect serum OPG. These changes may reflect an increase in the number of active osteoblasts with therapy and might be responsible for the acceleration of bone turnover rate that characterizes TPTD.

Sign in / Sign up

Export Citation Format

Share Document